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Probiotics and long-chain PUFA (LC-PUFA) may be beneficial supplements for infants who are not breast-fed. The aim of the present study is to
evaluate the safety of an infant formula containing the LC-PUFA DHA and arachidonic acid (AA) and the probiotic Bifidobacterium lactis by
comparing the growth rate of infants fed the supplemented and unsupplemented formulas. One hundred and forty-two healthy, term infants
were enrolled in a single-centre, randomised, double-blind, controlled, parallel-group trial, and allocated to receive either standard or probiotic
and LC-PUFA-containing experimental formulas. The infants were fed with their assigned formulas for 7months. The primary outcome
(weight gain) and the secondary outcomes (length, head circumference and formula tolerance) were measured throughout the study. LC-PUFA
status was assessed at 4 months of age and immune response to childhood vaccines was measured at 7months of age. There was no significant
difference in growth between the two groups. The 90% CI for the difference in mean weight gain was 20·08, 3·1 g in the intention-to-treat popu-
lation and 0·1–3·8 g in the per protocol population, which lay within the predefined boundaries of equivalence, 23·9–3·9. There were no signifi-
cant differences in mean length and head circumference. DHA and AA concentrations were higher in infants in the experimental formula group
compared with the control formula group. No influence of the supplements on the response to vaccines was observed. Growth characteristics of
term infants fed the starter formula containing a probiotic and LC-PUFA were similar to standard formula-fed infants.
Probiotics: Long-chain PUFA: Infant formula: Growth
The long-chain PUFA (LC-PUFA) DHA is found in high
concentrations in the retina and the brain. Pioneering work
in the early 1990s demonstrated that addition of DHA, using
fish oil supplements, to infant formulas of the day resulted
in improved visual acuity compared with matched, unsupple-
mented formulas in both preterm(1,2) and term infants(3).
However, some of these early studies suggested that infants
fed the fish oil-supplemented formulas had lower weight and
length gains than unsupplemented infants and that this was
related to the reduction in arachidonic acid (AA) status
caused by the addition of EPA and DHA found in the
marine oils used in the studies(2,4). Although most subsequent
trials have shown no negative effect of LC-PUFA supplemen-
tation on growth(5), they have tended to evaluate formulas
containing DHA and AA with little or no EPA. While this mir-
rors the composition of most currently marketed formulas with
LC-PUFA, there is an absence of systematic studies involving
newborn infants to assess the potential impact of the AA–EPA
balance in infant formulas. AA and EPA have important and
often contrasting functions as precursors of eicosanoids and
cyclo-oxygenase products, and modulate immune and inflam-
matory responses(6). Only two small studies from the same
laboratory have assessed the effect of infant formulas sup-
plemented with DHA and AA on immune markers, and
showed some modulation in lymphocyte populations and
cytokine production(7,8).
Breast-feeding promotes the colonisation of bifidobacteria
and lactobacilli that inhibit the growth of pathogenic micro-
organisms and compete with potentially pathogenic bacteria
for nutrients and epithelial adhesion sites. The gastrointestinal
flora may modulate mucosal physiology, barrier function and
systemic immunological and inflammatory responses(9–12).
*Corresponding author: Maria Makrides, fax þ61 8 8161 8228, email maria.makrides@cywhs.sa.gov.au
Abbreviations: AA, arachidonic acid; AE, adverse events; ITT, intention-to-treat; LC-PUFA, long-chain PUFA; PP, per protocol; SAE, AE were considered to be
serious.
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It is with this rationale that bifidobacteria and other probiotic
strains have been added to infant formulas. Studies show that
probiotic supplementation favourably alters infant gut micro-
biota and some studies suggest that certain probiotic bacteria
added after 5 months of age may protect against diarrhoea
and reduce the onset of allergy(13–17). However, it should be
noted that most trials assessing the safety and efficacy of pro-
biotics in infant formulas have not included infants in the first
4–6 months of age who are more vulnerable and have a less
developed immune system than their older counterparts(9).
We evaluated an infant formula for term infants containing
a probiotic, Bifidobacterium lactis, and the LC-PUFA DHA
and AA. Although these components have been added com-
mercially and are often accepted as safe(5,16,18–21), formulas
containing both components have not yet been studied for
safety in term infants. For this reason, the primary aim of
the present study was to assess the safety of the probiotic-
LC-PUFA combination by comparing the growth of term
infants who were fed the experimental formula with that of
infants fed a standard infant formula. Growth monitoring
remains the best method to assess the well-being of preverbal
children(20,21). As both probiotics and LC-PUFA have the
potential capacity to alter immune function and there is a
theoretical basis for synergistic action(22), we also compared
the antibody response of infants to vaccination, as well as
how the two test formulas were tolerated. Antibody response
to vaccination was chosen as the immune outcome because
it represents a systemic response related to a clinically import-
ant outcome(23).
Methods
Participants
Mothers of infants who chose to exclusively formula-feed
their infants were approached to enter the trial. Term ($37
weeks) and newborn infants (#10 d old) with birth weight
between 2500 and 4500 g were enrolled. Infants were
excluded from the study if: they had any congenital malfor-
mations or significant postnatal diseases; they were participat-
ing in another clinical trial; the parents were unwilling to
have infants immunised according to the National Health
and Medical Research Council (NHMRC) schedule(24) they
were unlikely to attend follow-up visits.
Trial design
The present study was a prospective, double-blind, controlled,
parallel-group, single-centre trial performed in Adelaide, Aus-
tralia (Women’s and Children’s Hospital, Children, Youth and
Women’s Health Service (CYWHS)) between August 2003
and May 2005. The primary objective was to demonstrate bioe-
quivalence of the experimental and control formulas based on
equivalent weight gain. The secondary objectives were to
assess the effects of the formula on immune response to immu-
nisation and blood biochemistry, infant tolerance andmorbidity.
Blinding of formulas was achieved by assigning two
colour codes to each test formula. Sealed, opaque envelopes
were prepared according to an independently generated
randomisation schedule, stratified by sex. Upon enrolment,
investigators gave the mothers the allocated formulas
according to the coding in the concealed envelopes along
with instructions on preparation. Infants were fed ad libitum
their allocated formula starting from the day of enrolment
until they were 212 ^ 7 d old (7months). Infants were
allowed to take weaning foods starting from 4 months of
age but they also had to be fed with at least 500ml/d of
their allocated formulas during this time. Follow-up home
visits took place when infants were 14 ^ 3 (V1), 28 ^ 3
(V2), 42 ^ 4 (V3) and 91 ^ 5 (V5) d old, and hospital visits
took place when they were 56 ^ 4 (V4), 119 ^ 6 (V6),
182 ^ 7 (V7) and 212 ^ 7 (V8) d old. Mothers/carers kept
records of the infants’ diet, stool characteristics, symptoms
of digestive tolerance and behaviour for 2 d before each
visit. At each visit, the research team recorded anthropometric
measurements and checked, and completed 2-d retrospective
dietary, tolerance and health history questionnaires. Immunis-
ation took place upon enrolment and approximately on days
56, 119 and 182. In brief, infants were immunised for hepatitis
B at enrolment and on days 56, 119 and 182, diphtheria, teta-
nus and pertussis on days 56, 119 and 182 and Haemophilus
influenzae type b on days 56 and 119, according to the
NHMRC immunisation schedule(24). Blood was drawn for
analysis of clinical biochemistry on day 119 to evaluate the
effect of the test formulas before the introduction of solids.
LC-PUFA status was also assessed at this time. Antibody
response to immunisation was assessed on day 212, 28 days
after the last immunisations for diphtheria, tetanus, pertussis
and hepatitis B and 90 d after the last immunisation for
H. influenzae type b.
Dietary intervention
Both formulas were whey predominant (70% whey and 30%
casein) and contained protein, carbohydrates, fats, vitamins
and minerals in quantities sufficient for the growth of healthy,
term infants (Table 1). In addition, the experimental formula
contained B. lactis (strain CNCM I-3446), fish oil DHA and
AA (Arasoftw; Sofinol, Switzerland). The B. lactis strain was
chosen because of its use in products for older infants and tod-
dlers. The dose of DHA was based on the average composition
in the breast milk of omnivorous women and to coincide with
the dose used in other trials(15). We rationalised that the dose
of AA should be equivalent to DHA to avoid an immune/inflam-
Table 1. Nutrient composition of the experimental and control formulas*
Constituent Experimental Control
Bifidobacterium lactis
(colony-forming units/100 kcal)
3·85 £ 108 Nil
Fatty acids (expressed as percentage of total fatty acids)
Total SFA 39·5 38·9
Total MUFA 41·6 41·6
18 : 2n-6 (Linoleic acid) 16·6 16·9
20 : 4n-6 (Arachidonic acid) 0·24 0
Total n-6 PUFA 17·0 17·0
18 : 3n-3 (a-Linolenic acid) 1·5 2·0
20 : 5n-3 (EPA) 0·07 0
22 : 6n-3 (DHA) 0·24 0
Total n-3 PUFA 1·8 2·0
*Both formulas provided 1·83 g protein/100 kcal, 5·3 g fat/100 kcal and 11·2 g
lactose/100 kcal.
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matory imbalance. Formulas were produced, blinded and sup-
plied by the manufacturer (Nestle´, Konolfingen, Switzerland).
Outcome measurements
The primary outcome was weight gain (g/d) from day 14 to
day 119 to cover the period of exclusively feeding the test
formulas. The secondary outcomes were recumbent length,
head circumference, BMI, biochemical measurement of
antibody titres, symptoms of digestive tolerance and occur-
rence of adverse events (AE). At each visit, anthropometric
measurements were taken by one of three trained anthropome-
trists. Over 50% of the assessments at day 14 and day 119
were done by a single person. Weight of infants was measured
to the nearest 10 g on electronic scales, recumbent length was
measured to the nearest 1mm on standardised length boards
and head circumference was measured to the nearest 1mm
using a standardised, non-elastic measuring tape. Evaluation
of digestive tolerance was based on: volume of formula
intake and any other dietary intakes; stool characteristics,
including frequency (number of stools per 24 h), predominant
colour (brown, yellow, green, red or black) and consistency
(hard, formed, soft or liquid); frequency of spitting up or
vomiting; behaviour (periods of restlessness or irritability
that lasted for .30min). AE were assessed at each visit by
a nurse. AE were defined as illnesses or signs or symptoms
occurring or worsening, or the occurrence of any abnormal
laboratory findings during the course of the study and classi-
fied according to the International Classification of Diseases-
10 criteria(25). AE were considered to be serious (SAE) if
they were fatal or life-threatening events causing permanent
harm or requiring or extending inpatient treatment at a hospi-
tal. The study investigators assessed the seriousness of an AE
and causal relation to the study products.
Blood (2ml) was drawn by venepuncture into heparinised
tubes and centrifuged. Red cells were separated and washed
three times with saline and lipids extracted for later fatty
acid determination. The plasma was frozen at2808C. Determi-
nation of the concentration of Hb, albumin, prealbumin, total
protein, urea, creatinine, ferritin, calcium, sodium, potassium,
chloride, phosphate and glucose were performed at SouthPath
Laboratory at Flinders Medical Centre. Titres of antibodies
against diphtheria and tetanus were measured by ELISA and
antibodies against hepatitis B were measured by Abbott
Axsym (automated analyser) in the Department of Micro-
biology at the Women’s and Children’s Hospital. Antibodies
against pertussis and H. influenzae type b were determined
by ELISA at the National Centre for Immunisation Research
and Surveillance, The Children’s Hospital at Westmead(23).
Lipids were extracted from red blood cells on the day of collec-
tion. Butylated hydroxyl anisole (0·005% (w/v)) was added to
the solvents (propanol and chloroform) used for lipid extrac-
tion. Total phospholipids were separated by TLC and the
fatty acid profile was determined by capillary GC at the
Child Nutrition Research Centre Laboratory at Flinders Medi-
cal Centre using previously described procedures(26).
Ethics
The present study was approved by the ethics committee
of CYWHS and was conducted in accordance with the
Declaration of Helsinki and its subsequent amendments.
Written informed consent was obtained from the legal
guardians of all infants. During the course of the study, we
became aware that the genome of B. lactis (strain CNMI-
3446) contained a gene that codes for tetracycline resistance.
On report to the Research Ethics Committee, an independent
expert review was commissioned. This review concluded
that the B. lactis strain was safe based on the following:
(a) the resistance was to an antibiotic that is not normally
used in children;
(b) tests to date have shown that the resistance gene does
not spread to other bacteria in the gut;
(c) the type of resistance is very common in a range of
probiotic products available commercially;
(d) the risks to the health of the child were negligible.
At the request of the Research Ethics Committee, a new
patient information sheet was prepared containing this
new information and participants already in the trial were re-con-
sented. All but one continued to feed their assigned test formula.
Statistical methods
Sample size calculation was based on the primary outcome,
which was weight gain. Growth of infants in the experimental
and control formula groups was considered equivalent when
the two-sided 90% CI of the difference in the means of
weight gain lay within the interval from 23·9 to þ3·9 g/d, a
standard that has been used in previous trials(27). The sample
size required to detect a difference in weight gain that is out-
side the 23·9 to þ3·9 g/d range based on an a-level of 0·05, a
power (1 2 b) of 0·9 and standard deviation of 6·1 g/d is forty-
eight per group (power analysis and sample size calculations
were performed by PASS 6.0; NCSS, Kaysville, UT, USA).
This sample size is slightly lower than the Food and Drug
Administration (FDA) requirement for clinical testing of
infant formulas; therefore, we based the present study on the
more conservative value of the FDA. According to the FDA
guidelines, twenty-eight infants of each sex per group would
have to be enrolled(28). Thus, fifty-six infants per group
would have to complete the study. Allowing for a 20% drop-
out, 140 infants had to be enrolled. The projected sample was
also consistent with the number of infants involved in other
dietary intervention trials assessing antibody titres to immunis-
ations(23).
The intention-to-treat (ITT) analysis was performed on all
randomised infants. The per protocol (PP) analysis excluded
the data from infants who were withdrawn from the study,
had a life-threatening event during the study, consumed .1
bottle per week of a different infant formula, did not consume
the experimental formula for $7 consecutive days, were intro-
duced to weaning food before 4 months of age, were hospital-
ised for $7 d or failed to complete the 14- or 119-d visit. The
primary outcome (growth) was analysed in both the ITT and
PP populations.
The mean difference in intake and growth measurements
between the experimental and control groups was estimated
by ANOVA correcting for sex. Growth measurements were
also compared with the Centers for Disease Control and
Prevention (CDC) references(29). Blood analysis data were
compared between groups using the t test (for normally
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distributed data) or Wilcoxon test (for skewed data). Stool
counts for each infant were aggregated and divided by the
number of days (counts/d), and the difference in frequency
between the two groups was analysed by the t test. The
number of days in which each stool colour and consistency
occurred and the number of days in which infants were
free of restlessness, flatulence, colic, spitting and vomiting
were compared between groups using logistic regression.
Finally, the incidence of AE (percentage of infants who had
experienced at least one AE) was compared between groups
with the exact x 2-test.
Statistical analysis was performed with SAS 8.02 (SAS
Institute, Cary, NC, USA)
Results
Study population
One hundred and forty-two infants were enrolled and random-
ised to the experimental (n 72) or control group (n 70). There
were no differences in the baseline characteristics between
infants in the two study groups (Table 2). Ten (13·8%) infants
from the experimental group and eight (11·4%) infants from
the control group were withdrawn or lost to follow-up
before the end of the study (Fig. 1). Twenty-seven infants
did not follow the required dietary restriction (used non-
study formulas or introduced solid food before 4 months of
age) and therefore their data were excluded from the PP
analysis. Since one infant in the experimental group dropped
out only after the sixth visit (day 119 of age), the infant’s
data were available for growth analysis and the infant was
kept in the PP population.
Formula intake and growth
The mean volume of formula intake tended to be higher in the
experimental group compared with the control group through-
out the study (data not shown), but was significantly higher
only on days 56 and 91 (mean and standard deviation for
ITT: 853 (SD 169) v. 785 (SD 175) ml/d, P¼0·04 and 939
(SD 169) v. 855 (SD 183) ml/d, P¼0·01, respectively; for
PP: 855 (SD 162) v. 771 (SD 168) ml/d, P¼0·02 and 936 (SD
172) v. 866 (SD 185) ml/d, P¼0·05, respectively). The mean
daily volume of formula intake over the course of the entire
study was also significantly higher in the experimental group
compared with the control group (ITT: 873 (SD 152) ml/d v.
799 (SD 151) ml/d, t test P¼0·001; PP: 893 (SD 130) v. 830
(SD 134), P¼0·014).
There were no significant differences in weight between the
two groups throughout the study (data not shown). Mean
weight gain (from day 14 to day 119) between the experimen-
tal and control groups was 1·5 and 2·0 g/d for the ITT and PP
populations, respectively. The 90% CI (ITT: 20·08–3·1 g/d
and PP: 0·1–3·8 g/d in the PP population) lay within the
23·9 to þ3·9 g/d interval, indicating equivalent growth
among infants in the two groups. Similarly, the mean changes
in length, head circumference and BMI were not significantly
different between the two groups (Table 3). A comparison of
weight-for-age, length-for-age and head circumference-for-age
with the CDC growth references showed that z-scores were
within the normal ranges for both groups (data not shown).
Biochemical and immunological analyses
On day 119, the concentrations of DHA, AA and EPA in red
blood cell membranes were significantly higher among infants
in the experimental group compared with those in the control
group (Table 4). On the other hand, the concentrations of
linoleic acid and a-linolenic acid were higher in infants in
the control group. Both results are reflective of the fat compo-
sition of the formulas (Table 1).
None of the standard blood biochemical measurements dif-
fered between the two groups (data not shown), except that the
measurements of blood glucose and albumin concentrations
were higher in the control group (4·7 (SD 0·5) v. 4·4 (SD 0·7)
mmol/l, P¼0·012 for glucose and 40·8 (SD 2·5) v. 39·5
(SD 2·9) g/l, P¼0·03 for albumin). However, all values are
within the normal range for infants.
On day 212, therewere no differences between the control and
experimental groups in the geometric mean titres of antibodies
against diphtheria (0·82 v. 0·92 IU/ml, respectively), H. influen-
zae type b (2·23 v. 2·01mg/ml, respectively), hepatitis B (27·11
v. 24·53 IU/ml, respectively), pertussis filamentous haemagglu-
tinin (3·67 IU/ml for both groups), pertussis pertactin (4·06 IU/
ml for both groups), pertussis toxin (2·46 v. 2·23 IU/ml, respect-
ively) and tetanus (1·11 IU/ml for both groups).
Digestive tolerance
In general, stool characteristics were similar between the two
groups (data not shown). However, green stools occurred sig-
nificantly less frequently (25·6 (SD 22·5) v. 33·3 ^ 25·5%,
P¼0·002) and yellow stools occurred significantly more
frequently (67·6 (SD 25·2) v. 50·3 ^ 27·3%, P,0·001)
among infants in the experimental group. Stools, colic, spitting
up, vomiting and restlessness occurred at similar frequencies
in the two groups (data not shown).
Adverse events
During the study, 403 AE were reported in 124 infants (sixty
in the experimental and sixty-four in the control groups) in the
ITT population (Table 5). The most common AE were infec-
tions, dermatitis, digestive problems and feeding problems
(vomiting during or right after feeding), and only the fre-
quency of feeding problems was significantly lower in the
Table 2. Baseline characteristics of infants (intention-to-treat)*
(Mean values and standard deviations)
Experimental
(n 72) Control (n 70)
Characteristics Mean SD Mean SD
Female (%) 56 53
Caesarean birth (%) 44 27
Antibiotic use (%) 29 34
Gestational age (weeks) 39 1·3 39·1 1·2
Weight at birth (g) 3412 481·7 3241 400·3
Length at birth (cm) 49·6 2·1 49·3 2
BMI at birth (kg/m2) 13·8 1·2 13·3 1·3
Head circumference at birth (cm) 34·7 1·4 34·1 1·2
* There were no significant differences between groups.
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experimental group compared with the control group
(P¼0·03). Forty AE in twenty-nine infants (eighteen in the
experimental and eleven in the control groups) were reported
as serious (SAE), and were similarly distributed among the
two groups (P¼0·21). All SAE required hospitalisation of
infants. The most frequently occurring SAE were respiratory
problems (seven in the experimental and four in the control
groups) and gastrointestinal problems (three in each group).
Most of the SAE were considered to be unrelated (n 20) or
unlikely to be related (n 17) to the formulas. Three SAE con-
sidered to be probably related to the formulas were gastroin-
testinal problems (one in each group) and a respiratory
problem in the control group. There were no deaths.
Discussion
In the present study, we evaluated the safety of a formula
containing the probiotic B. lactis and the LC-PUFA DHA
and AA, by comparing the weight gain of infants fed the
Fig. 1. Trial profile. ITT, intention-to-treat; PP, per protocol.
Table 3. Mean changes in anthropometric measurements during the
study (per protocol)*
(Mean values and standard deviations)
Experimental Control
Sex n Mean SD n Mean SD
Weight (g/d) M 24 33·6 7·5 19 31·6 7·7
F 31 28·1 5·8 24 26·5 4·9
Length (mm/month) M 24 35 3·7 19 37·3 4·9
F 27 32·8 4 23 32 4·6
Head circumference
(mm/month)
M 23 18 2·4 19 17·5 3·4
F 29 16·1 2·7 24 16 3
BMI (kg/cm2/month) M 24 1·1 0·6 19 1 0·5
F 27 0·9 0·5 23 0·8 0·4
M, males; F, females.
*Treatment differences of anthropomorphic measurements were estimated by a
mixed model corrected for sex. There were no significant differences between
groups.
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experimental formula with that of infants fed a similar formula
lacking these components. There was no difference in weight
gain between infants in the two groups during the study period
(day 14–day 119). Other growth parameters also showed no
differences at any of the time points, confirming that growth
was similar in the two groups. While individual components
such as B. lactis or LC-PUFA are added for benefit, it is
important that the combination of such novel components is
also tested for safety.
It has previously been reported that decreases in the concen-
tration of plasma AA in preterm infants, due partly to the
addition of n-3 LC-PUFA in infant formulas, correlated with
a decrease in growth(30). Subsequently, it has been proposed
that n-3 LC-PUFA supplementation should occur in conjunc-
tion with AA to avoid lowering the plasma and erythrocyte
concentrations of AA. This has led to a discussion relating
to the best ratio of n-3 LC-PUFA and AA for infant formula,
and recommendations suggesting that a 1:2 ratio may be opti-
mal. Our earlier trial assessing DHA and AA at a concen-
tration of 0·34% of total fatty acids in a 1:1 ratio(31) as well
as the present study assessing a concentration of 0·23% of
DHA and AA in a 1:1 ratio both demonstrate equivalent
growth and increase the erythrocyte concentrations of both
DHA and AA relative to the control, unsupplemented infant
formula. These data imply that a 1:1 ratio of DHA to AA
does not result in a reduction in AA status across different
concentrations. A 1:1 ratio of DHA to AA also falls within
the range of human milk values reported worldwide and
summarised in a recent review(32). Furthermore, recent
analyses of randomised trials with term infants receiving
formula supplemented with only n-3 LC-PUFA (and causing
a reduction in infant AA status) have not shown any effect
on growth(5,21). Addition of probiotics to infant formulas has
not been associated with any reports of growth effects in
term infants. However, the effect of combining LC-PUFA
and probiotics was not known, although there is no reason
to believe a priori that delivery of the combination of these
two components would affect growth.
Das(22) proposed that the combination of LC-PUFA and
probiotics may be beneficial, since LC-PUFA help to colonise
the nascent microbiota of infants by probiotics and enhance
adherence of probiotics to gut mucosal cells. LC-PUFA
themselves have been shown to modulate components of the
immune system. Field et al. (7) showed that dietary fatty
acids have an effect on several functional indices of immune
development (increased concentration of antigen-mature
T-cells and increased production of IL10) in preterm infants.
Other possible effects include stimulating lymphocyte
proliferation, cytokine production, natural killer cell activity
and antigen presentation (reviewed in Field et al. (33)).
A comparison of titres of IgG against diphtheria, H. influen-
zae type b, hepatitis B, pertussis and tetanus vaccines when
infants were approximately 7 months of age (1 month after
they had completed a primary immunisation course) showed
that there were no differences between the two groups. The
present study was powered to detect differences in weight
gain and may not have been sufficiently powered to detect
differences in IgG concentrations following immunisation,
although other trials of formula feeding have shown differ-
ences in vaccine titres with similar numbers of infants(23).
Since infants mount a strong response to vaccines, especially
after several doses, it may be difficult to observe subtle effects
of LC-PUFA and probiotics on the immune response.
Measurement of antibody titres after the first immunisation
may give a better indication of the effect on the immune
response. Alternatively, effects on the immune response may
be more evident for vaccines that are delivered orally or via
other mucosal routes. Indeed, de Vrese et al. (34) showed
that probiotics enhanced the antibody response to orally deliv-
ered polio vaccine. A different group studying the effect of
probiotics on the vaccination response in infants suggested
that probiotics may improve the immune response to H. influ-
enzae type b vaccine, whereas there was no indication of
any effect on the antibody response to diphtheria and tetanus
vaccines(35).
Table 4. Fatty acid concentration (percentage of total phospholipid fatty acid) in erythrocyte membranes on day 119 (per protocol population)
(Mean values and standard deviations)
Fatty acids
Experimental (n 52) Control (n 40)
P *Mean SD Mean SD
a-Linolenic acid 0·09 0·01 0·15 0·02 ,0·0001
Eicosapentaenoic acid 0·35 0·04 0·26 0·03 ,0·0001
n-3 Docosapentaenoic acid 1·43 0·14 1·87 0·12 ,0·0001
Docosahexaenoic acid 6·18 0·58 2·8 0·38 ,0·0001
Total n-3 fatty acids 8·11 0·54 5·03 0·36 ,0·0001
Linoleic acid 10·18 0·72 11·89 0·72 ,0·0001
Arachidonic acid 14·52 0·91 13·97 0·96 0·006
Total n-6 fatty acids 30·87 0·58 33·44 0·70 ,0·0001
*Comparison by the t test; P,0·05 was considered significant.
Table 5. Adverse events (percentage of affected infants) occurring in
the intention-to-treat population and classified according to the Inter-
national Classification of Diseases-10 criteria
Specific AE Experimental (n 72) Control (n 70)
Intestinal infectious disease 29 41
Symptoms and signs involving
the digestive system
15 11
Feeding problems of newborns 15 31*
Respiratory infections 65 70
Candidiasis 8 13
Dermatitis 18 16
AE, adverse events.
* No significant difference among groups by the x 2-test except P,0·05.
Long-chain-PUFA and probiotics in formula 1711
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114508084080
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:32:19, subject to the Cambridge Core terms of use, available at
Interestingly, fewer parents with infants in the LC-PUFA
and probiotic group reported feeding problems of the newborn
compared with the control. This International Classification of
Diseases-10 classification mostly describes vomiting during or
directly after a feed that is not associated with fever or other
gastrointestinal symptoms such as diarrhoea. Whether this
finding indicates improved tolerance in infants fed the exper-
imental formula is not clear because our sample size was too
small to exclude the possibility of random error.
In the present study, over 50% of families with eligible
infants consented to participate and, of these, 87% completed
the trial. The high participation rate and retention rate for this
type of trial point towards a robust internal and external
validity of the trial data, which demonstrate that an experi-
mental formula with LC-PUFA and probiotics promotes
normal growth of term infants. Additional studies are
required to determine whether the combination of LC-
PUFA and probiotics has any functional effect on the infants’
immune system.
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